Understanding AAV vector immunogenicity: from particle to patient
Theranostics · 2024 · 14 (3) · 1260-1288
DOI: 10.7150/thno.89380 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Theranostics, 2024. Verfasst von Bijay P Dhungel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Gene and Stem Cell Therapy Program Centenary Institute, The University of Sydney, NSW, Australia. Hauptthemen laut MEDLINE: Genetic Vectors, Antibodies, Neutralizing. Die Arbeit wurde bisher 93-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gene and Stem Cell Therapy Program Centenary Institute, The University of Sydney, NSW, Australia.
- Faculty of Medicine and Health, The University of Sydney, NSW, Australia.
- Pfizer Inc, Walton on the Hill, Surrey, UK.
- Pfizer Australia, Sydney, NSW, Australia.
- Pfizer Inc, New York, NY, USA.
- Cell and Molecular Therapies, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
Zitieren
APA
Dhungel, B. P., Winburn, I., Pereira, C. D. F., Huang, K., Chhabra, A., & Rasko, J. E. J. (2024). Understanding AAV vector immunogenicity: from particle to patient. Theranostics, 14(3), 1260-1288. https://doi.org/10.7150/thno.89380
Vancouver
Dhungel BP, Winburn I, Pereira CDF, Huang K, Chhabra A, Rasko JEJ. Understanding AAV vector immunogenicity: from particle to patient. Theranostics. 2024;14(3):1260-1288. doi:10.7150/thno.89380
BibTeX
@article{Dhungel2024,
author = {Dhungel, Bijay P and Winburn, Ian and Pereira, Candida da Fonseca and Huang, Kui and Chhabra, Amit and Rasko, John E J},
title = {Understanding AAV vector immunogenicity: from particle to patient},
journal = {Theranostics},
year = {2024},
volume = {14},
number = {3},
pages = {1260--1288},
doi = {10.7150/thno.89380}
}
EUVIMED